Tag: cancer
-
Saliva Test IDs Early Oral Cancer Signature
An analysis is shown to identify characteristic patterns found in microbial communities in saliva indicating early stages of oral and throat cancer.
-
$180M Venture Fund Backing Age-Related Disease Start-Ups
A new venture capital fund aims to finance research entrepreneurs addressing root causes of age-related diseases with therapies and early diagnostics.
-
Regeneron Gains Cancer, Infectious Disease Immunotherapies
A biotechnology company is licensing five of its vaccines for cancer and infectious diseases to Regeneron Pharmaceuticals in a deal valued at nearly $1 billion.
-
Trial Advances Test of Electronic Cancer Treatment
A clinical trial completed enrollment of lung cancer patients testing a device sending an electric field into their tumors to disrupt cancer cell proliferation.
-
Targeted Immunotherapy Shown to Shrink, Stop Tumors
Results from tests with lab mice show an experimental targeted cancer therapy invoking the immune system shrinks tumors and prevents their recurrence.
-
Joint Venture to Develop Stable RNA Covid-19 Vaccine
A developer of synthetic bio-based products from engineered yeast cells is joining with an immunotherapy drug maker to produce a stable RNA Covid-19 vaccine.
-
FDA Halts Off-the-Shelf T-Cell Cancer Trials
The Food and Drug Administration stopped a company’s clinical trials of off-the-shelf engineered T-cells after a patient showed an abnormal chromosomal reaction.
-
Partnership Seeks Lower-Cost Protein Drugs
A biotechnology enterprise and company aiming to make drugs at lower prices are collaborating on new lower-cost synthetic protein drugs.
-
Genomic Analysis Shown to Detect Early Pancreatic Cancer
Analysis of genomic and protein indicators in blood samples is shown to detect pancreatic cancer in earlier stages, increasing chances of survival.
-
Off-the-Shelf Stem Cell Company Forms, Gains $72M
A new enterprise developing packaged blood-forming stem cells as therapies for a range of diseases began operations and raised $72 million in venture funds.